根据提交给美国证券交易委员会（SEC）的文件，HCW Biologics Inc. 已达成一项协议，该协议预计将于2026年5月1日或前后正式启动。不过，此项协议的执行，明确以该公司成功完成其当前计划中的公开发行（Public Offering）为先决条件。这意味着，只有在公开发行顺利结束之后，协议才会正式生效。
根据提交给美国证券交易委员会（SEC）的文件，HCW Biologics Inc. 已达成一项协议，该协议预计将于2026年5月1日或前后正式启动。不过，此项协议的执行，明确以该公司成功完成其当前计划中的公开发行（Public Offering）为先决条件。这意味着，只有在公开发行顺利结束之后，协议才会正式生效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.